Core Viewpoint - The Hong Kong Stock Connect Central State-Owned Enterprises Dividend ETF (159266) experienced a net redemption of 4.0133 million yuan on February 3, ranking 38th out of 212 in cross-border ETF net outflows [1] Group 1: Fund Performance - As of February 3, the latest size of the Hong Kong Stock Connect Central State-Owned Enterprises Dividend ETF (159266) is 562 million yuan, down from 564 million yuan the previous day, with a net outflow of 0.71% of the previous day's size [1] - Year-to-date, the fund's shares have decreased by 9.58% and its size has decreased by 8.03% compared to December 31, 2025, when the shares were 616 million and the size was 611 million yuan [2] Group 2: Liquidity and Trading Activity - Over the last 20 trading days, the cumulative trading amount for the ETF is 254 million yuan, with an average daily trading amount of 12.6913 million yuan [2] - In the 22 trading days this year, the cumulative trading amount is 266 million yuan, with an average daily trading amount of 12.0983 million yuan [2] Group 3: Fund Management and Holdings - The current fund managers are Liu Tingyu and Cai Leping, with Liu managing the fund since July 23, 2025, achieving a return of 0.96%, while Cai has managed it since November 5, 2025, with a return of -1.82% [2] - Major holdings in the fund include China COSCO Shipping, China Shenhua Energy, CNOOC, Sinopec Engineering, China National Offshore Oil Corporation, and others, with respective holding percentages and market values detailed [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 基金管理人： 华泰柏瑞基金管理有限公司 基金托管人： 中信建投证券股份有限公司 发售主协调人：中信建投证券股份有限公司 重要提示 1、华泰柏瑞恒生生物科技交易型开放式指数证券投资基金（以下简称"本基金"）的募集已根据2026年1 月7日中国证监会《关于准予华泰柏瑞恒生生物科技交易型开放式指数证券投资基金注册的批复》（证 监许可[2026]47号）注册。 2、本基金是交易型开放式、股票型指数证券投资基金。 基金简称：华泰柏瑞恒生生物科技ETF 场内简称：香港生科 扩位证券简称：恒生生物科技ETF华泰柏瑞 基金认购代码：513933；基金证券代码：513930。 3、本基金的基金管理人为华泰柏瑞基金管理有限公司（以下简称"本公司"），基金托管人为中信建投 证券股份有限公司，本基金的基金登记机构为中国证券登记结算有限责任公司。 4、本基金发售对象为符合法律法规规定的可投资于证券投资基金的个人投资者、机构投资者、合格境 外投资者以及法律法规或中国证监会允许购买证券投资基金的其他投资人。 5、本基金自2026年2月24日至2026年3月4日进行发售。本基金的投资人可选择 ...

港股通数据统计周报 2026.01.26-2026.02.01 | 分析师： | 蒋开来 | | --- | --- | | 中央编号： | BWL381 | | 联系电话： | 852-6430 1060 | | 邮箱： | jiangkl@cnzsqh.hk | 1 目录 2 l 港股通前十大净买入/卖出公司 l 港股通净买入/卖出行业分布 l 港股通前十大活跃个股 l 港股通与南下资金介绍 港股通前十大净买入/卖出公司 3 港股通本周前十大净买入公司（2026.01.26-2026.02.01） | 序号 | 证券代码 | 证券简称 | 行业 | 港股通持股变动数 | 净买入金额（亿元） | | --- | --- | --- | --- | --- | --- | | 1 | 9992.HK | 泡泡玛特 | 可选消费 | 13440803 | 30.05 | | 2 | 0700.HK | 腾讯控股 | 信息技术 | 4621172 | 28.00 | | 3 | 1810.HK | 小米集团-W | 信息技术 | 49988528 | 17.75 | | 4 | 2628.HK | 中国人寿 | ...

Core Viewpoint - Guoen Technology is set to launch its global offering on January 27, with a pricing range of HKD 34-42 per share, aiming for a total issuance scale of approximately HKD 10.2 billion to 12.6 billion. The market is discussing the rationality of its pricing, stock price stability post-listing, and long-term valuation logic due to various factors including its business structure and competitive landscape [1][4][11]. Group 1: Financial Performance - Guoen Technology's revenue for 2022-2024 is projected at CNY 134 billion, CNY 174 billion, and CNY 192 billion, with a compound annual growth rate (CAGR) of 19.6%. However, growth is expected to slow to 9.9% in the first ten months of 2025 [2][3]. - The company's net profit has shown significant volatility, with figures of CNY 6.6 billion, CNY 4.7 billion, CNY 6.9 billion, and CNY 7.1 billion for the same periods, reflecting fluctuations of 3.1%, -29.7%, 45.2%, and 40.2% respectively [2][3]. Group 2: Cost Structure and Profitability - Raw material costs account for over 90% of sales costs, leading to limited profitability. The gross margin has declined from 11.8% to 8.3% from 2022 to 2024, with a slight recovery to 10.4% in the first three quarters of 2025 [3][11]. - The health sector shows stronger profitability potential, with a gross margin of 22.5% in the first ten months of 2025, but its revenue contribution is only 3.5%, insufficient to offset the low margins from the chemical sector [3][11]. Group 3: Market Position and Investor Interest - Guoen Technology's market capitalization of CNY 151 billion is the smallest among five concurrent A to H projects, which may reduce its attractiveness to institutional investors [4][5]. - The company has attracted eight cornerstone investors, raising USD 4.1 million, with significant investments from local and health-focused entities, indicating a strategic interest in its health sector [6][8]. Group 4: Market Dynamics and Risks - The absence of a greenshoe option in the offering raises concerns about stock price stability post-listing, as it lacks market support mechanisms [9][10]. - The Hong Kong market's preference for high-growth sectors may limit Guoen Technology's valuation, as its chemical business faces inherent valuation discounts compared to high-margin sectors [11].

自去年8月8日盘中触及19.90港元阶段性高点后，博安生物(06955)的股价便开启了一轮长达5个多月的下跌行情。今年1月5日盘中，博安生物股价触及年内新 低8.15港元，让这段下跌行情的股价高低振幅达到59.05%。 智通财经APP观察到，得益于去年上半年的上涨行情，即使在去年年末市值仅剩53.12亿港元的情况下，博安生物依旧凭借其2025年第二期港股通检讨期内 的65.65亿港元日均市值，在当时港股通调出门槛60.26亿港元上顺利卡位，实现成功"保通"。 然而，这根大阳线并未提振市场情绪，在接下来的行情中，技术面上，博安生物的BOLL线出现了明显的收窄趋势，引导股价持续震荡下跌，而公司股价也 基本沿BOLL线中下轨作机械震荡，且整体走势呈现出无量空跌状态。在这段长达4个月的持续低价行情中，威美控股甚至仅有4个交易日的日成交量超过 1000万股，市场交投情绪较此前明显更加低迷。 即使在去年11月27日出现了一波冲击BOLL线上轨的走势，但均未观察到明显的成交量放大支持，也没有形成有效实体K线突破，在技术面上属于典型的 BOLL线指标"假突破"，后续公司股价依旧震荡下跌至今年1月2日的盘中低点。 结合量能来看 ...

相关事件 港股异动丨南华期货股份创上市新高，已被纳入港股通 南华期货股份(02691.HK)：稳定价格期间结 束、并无采取稳定价格行动及超额配股权失效 延续昨日涨势，南华期货股份(2691.HK)今日盘中再度涨近10%至12.5港元，股价创上市新高。消息面 上，1月19日，南华期货股份获纳入港股通。另外，南华期货近日在互动平台回答投资者提问时表示， 公司境内外经纪业务、场外衍生品业务等相关业务涉及黄金、白银等期货品种。华西证券此前指，公司 期货业务牌照齐全，全球化布局成效显著，境外业务具备优势，将继续作为公司业务的主要抓手，帮助 公司实现快速发展。 ...

消息面上，近期，南华期货在互动平台回答投资者提问时表示，公司境内外经纪业务、场外衍生品业务 等相关业务涉及黄金、白银等期货品种。华西证券（002926）此前指，公司期货业务牌照齐全，全球化 布局成效显著，境外业务具备优势，将继续作为公司业务的主要抓手，帮助公司实现快速发展。此外， 南华期货股份近日正式获纳入港股通。分析人士认为，公司获纳入港股通有望显著提升其交易流动性。 南华期货（603093）股份(02691)盘中涨超9%，触及12.5港元创上市新高。截至发稿，涨8.18%，报12.3 港元，成交额1.44亿港元。 ...

消息面上，近期，南华期货在互动平台回答投资者提问时表示，公司境内外经纪业务、场外衍生品业务 等相关业务涉及黄金、白银等期货品种。华西证券此前指，公司期货业务牌照齐全，全球化布局成效显 著，境外业务具备优势，将继续作为公司业务的主要抓手，帮助公司实现快速发展。此外，南华期货股 份近日正式获纳入港股通。分析人士认为，公司获纳入港股通有望显著提升其交易流动性。 智通财经APP获悉，南华期货股份(02691)盘中涨超9%，触及12.5港元创上市新高。截至发稿，涨 8.18%，报12.3港元，成交额1.44亿港元。 ...

Fund Overview - The fund is named "Fullgoal Value Return Mixed Securities Investment Fund" and is classified as a mixed securities investment fund [12] - The fund will be publicly offered from February 4, 2026, to March 3, 2026, with the possibility of adjusting the fundraising period based on subscription conditions [15][18] - The minimum total subscription amount for the fund is set at 200 million units, equivalent to 200 million RMB [16] Subscription Details - The minimum subscription amount for individual investors is 10 RMB, while the minimum for direct sales is 50,000 RMB for the first subscription and 20,000 RMB for additional subscriptions [19][3] - Investors can subscribe multiple times during the fundraising period, and subscriptions through direct sales do not incur subscription fees [19][22] - The fund's subscription fee structure varies, with A class shares having fees when subscribed through distribution agencies, while C class shares do not incur any subscription fees [22][31] Sales Institutions - The fund is managed by Fullgoal Fund Management Co., Ltd., with China Agricultural Bank serving as the fund custodian [50][51] - Direct sales can be conducted through the company's direct sales center located in Shanghai, while distribution can also occur through China Agricultural Bank [13][52] Investor Requirements - Investors must open a fund account with the management company to subscribe, and only one account per investor is allowed [2][6] - Personal investors must provide valid identification and complete necessary forms when subscribing [35][36] Fund Management and Fees - The fund employs a floating management fee model, which may vary based on the holding period and annualized return [10] - The fund's net asset value may fluctuate due to market volatility, and past performance does not guarantee future results [9][15]

消息面上，1月19日，南华期货股份获纳入港股通。分析人士认为，公司获纳入港股通有望显著提升其 交易流动性。此外，目前南华期货H股较A股有明显折价，或将吸引大量内地投资者出手，南华期货的 AH股股价联动将更紧密，其H股或将迎来价值重估。 值得注意的是，南华期货近期表示，公司境内外经纪业务涉及黄金、白银等期货品种。招股书显示，南 华期货计划将H股上市的全球发售所得额净额全部分配给开展境外业务的横华国际，以增强中国香港、 英国、美国及新加坡境外附属公司的资本基础，扩大公司的境外业务，优化境外业务结构，并增强南华 期货在全球市场的竞争力和风险承受能力。 南华期货股份(02691)早盘涨超11%，截至发稿，涨8.88%，报11.4港元，成交额3765.33万港元。 智通财经APP获悉，南华期货股份(02691)早盘涨超11%，截至发稿，涨8.88%，报11.4港元，成交额 3765.33万港元。 ...